Business · Companies · 59 mins ago
Lunit AI to help Summit identify biomarkers for cancer drug
South Korea’s Lunit will work with US biotech firm Summit Therapeutics on research for ivonescimab, an experimental cancer drug.
Lunit will use its AI platform to examine existing tumor tissue slides and analyze how cancer and immune cells are arranged.
The goal is to find biomarkers that could help identify which patients may respond to the drug and explain how it works.
Ivonescimab targets two proteins and is being studied in clinical trials for several cancers, including lung cancer.
Summit is leading global development of the drug under rights licensed from China’s Akeso.
The partnership comes as AstraZeneca has announced a $2 billion investment in Summit and plans to develop ivonescimab with one of its cancer medicines.
Results may guide future research and clinical development plans, but the companies have not announced a timeline for the AI work.
Lunit and Summit Therapeutics are collaborating to use artificial intelligence to identify biomarkers for Summit’s cancer drug ivonescimab.
The work will analyze the tumor microenvironment and may help identify patients likely to respond to treatment.
Lunit’s Lunit SCOPE IO platform will analyze existing H&E tissue slides without additional staining or tests.
Yonhap said Lunit announced the research collaboration on October 24, while Donga Ilbo reported it on October 26.
- Who
- South Korean medical AI company Lunit and US biotechnology company Summit Therapeutics.
- What
- They are collaborating to use AI analysis to identify biomarkers for the cancer drug ivonescimab.
- When
- Lunit announced the collaboration on October 24, according to Yonhap; Donga Ilbo said it announced it on October 26.
- Where
- The collaboration concerns Summit’s drug development program; Summit is headquartered in Miami, Florida.
- Why
- The companies aim to analyze the tumor microenvironment, identify biomarkers and support research into treatment response.
This story does not have two clearly opposing sides.
At the World Conference on Lung Cancer, results were presented showing ivonescimab improved overall survival compared with Keytruda in patients with PD-L1-positive non-small-cell lung cancer.
Yonhap said Lunit announced its research collaboration with Summit on its website.
Donga Ilbo reported the collaboration; Lunit shares were up 26.19% in early trading, according to Yonhap.
- Drug
- Ivonescimab
- AI platform
- Lunit SCOPE IO
- Tissue analysis
- H&E slides
- Summit headquarters
- Miami, Florida
- Clinical results
- Positive data reported in five phase 3 trials to date
- Lunit share move
- Up 26.19% at 9:30 a.m. on October 26, 2026
3 sources
What people are saying
It is significant that Summit, a leader in developing next-generation immunotherapies, is using Lunit’s AI technology in research on ivonescimab.
As immunotherapies develop toward more complex mechanisms of action and combination therapies, understanding the tumor microenvironment is becoming increasingly important.